Stockscreener 앱 받기
13.45
4.35%
0.57
전일 마감가:
$12.88
열려 있는:
$12.89
하루 거래량:
442.39K
Relative Volume:
0.39
시가총액:
$671.88M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-3.645
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
+7.43%
1개월 성능:
-12.67%
6개월 성능:
+37.42%
1년 성능:
+12.00%
1일 변동 폭
$12.81
$13.49
1주일 범위
$12.18
$13.49
52주 변동 폭
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.45 | 643.40M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.27 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.73 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.06 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.06 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.49 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
How institutional ownership impacts KalVista Pharmaceuticals Inc. stockJuly 2025 Highlights & Community Supported Trade Ideas - Newser
KalVista Pharmaceuticals Inc. stock trend outlook and recovery path2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Will KalVista Pharmaceuticals Inc. benefit from macro trendsWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Does KalVista Pharmaceuticals Inc. qualify in momentum factor screening2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can swing trading help recover from KalVista Pharmaceuticals Inc. lossesBuy Signal & Momentum Based Trading Signals - Newser
Is KalVista Pharmaceuticals Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Accurate Technical Buy Alerts - Newser
Applying Wyckoff theory to KalVista Pharmaceuticals Inc. stockJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
Intraday pattern recognizer results for KalVista Pharmaceuticals Inc.July 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Measuring KalVista Pharmaceuticals Inc.’s beta against major indices2025 Earnings Surprises & Entry Point Strategy Guides - Newser
What makes KalVista Pharmaceuticals Inc. stock price move sharplyAnalyst Downgrade & Risk Adjusted Buy/Sell Alerts - sundaytimes.kr
Regulatory Risk and Reward: Navigating FDA Delays in the ALS Therapeutics Landscape - AInvest
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union - BioSpace
KalVista Pharmaceuticals Announces Maintenance of Orphan Designa - GuruFocus
How to integrate KalVista Pharmaceuticals Inc. into portfolio analysis toolsFree Market Entry and Exit Point Tips - Newser
FDA approved six NMEs in July - BioCentury
KalVista Pharmaceuticals Grants Stock Options to New Hires - AInvest
KalVista Pharmaceuticals shares rise 3.68% premarket after announcing inducement grants to new employees. - AInvest
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Reversal Traders Monitor KalVista Pharmaceuticals Inc. for EntryFundamental Growth Stock Analysis Shows Strength - metal.it
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
Published on: 2025-08-04 07:21:19 - Jammu Links News
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsBuild wealth steadily with proven stock picks - Jammu Links News
What institutional investors are buying KalVista Pharmaceuticals Inc. stockRapid wealth creation - Jammu Links News
Is KalVista Pharmaceuticals Inc. stock overvalued or undervaluedMaximize your portfolio’s earning power - Jammu Links News
What analysts say about KalVista Pharmaceuticals Inc. stockInvest confidently with actionable market data - Jammu Links News
What are the technical indicators suggesting about KalVista Pharmaceuticals Inc.Unstoppable investment returns - Jammu Links News
When is KalVista Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent profits with expert strategies - Jammu Links News
What drives KalVista Pharmaceuticals Inc. stock priceConsistently profitable trades - Jammu Links News
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastUnlock exclusive investment alerts - Jammu Links News
What is the risk reward ratio of investing in KalVista Pharmaceuticals Inc. stockAdvanced Screener Growth Plan For Every Investor - Jammu Links News
What are KalVista Pharmaceuticals Inc. company’s key revenue driversAI Powered Tracker That Work - Jammu Links News
Does KalVista Pharmaceuticals Inc. stock pay reliable dividendsPredictable Income Summary for Long-Term Trades - Newser
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - MSN
Published on: 2025-07-29 19:52:44 - metal.it
Sebetralstat recommended for EU approval for treating HAE attacks - Angioedema News
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - Jammu Links News
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.30%
자본화:
|
볼륨(24시간):